Lundbeck Advances Movement Disorders Pipeline with Key Data at MDS 2026
Event summary
- Lundbeck will present data on amlenetug, its investigational treatment for multiple system atrophy (MSA), at MDS 2026, including baseline characteristics from the Phase III MASCOT trial.
- The MASCOT trial enrolled 401 participants with clinically probable or established MSA, with results expected in Q3 2027.
- Lundbeck will also share Phase Ib data for Lu AF28996, a novel oral D1-like/D2-like dopamine receptor agonist for advanced Parkinson's disease.
- Additional research includes biomarker identification, diagnostic tools, and healthcare burden studies in MSA.
The big picture
Lundbeck's focus on movement disorders aligns with the growing need for innovative treatments in neuroscience, particularly for rare conditions like MSA and advanced Parkinson's disease. The company's expanding scientific program underscores its commitment to addressing high-need areas with significant unmet medical requirements. The strategic emphasis on biomarkers and diagnostic tools could enhance the efficiency of future clinical development efforts.
What we're watching
- Clinical Trial Outcomes
- Whether the Phase III MASCOT trial results for amlenetug in Q3 2027 will demonstrate efficacy and safety in MSA, a rare and rapidly progressing neurodegenerative disease.
- Pipeline Progression
- The pace at which Lu AF28996 advances through Phase II development for advanced Parkinson's disease, particularly its potential to address motor complications.
- Biomarker Validation
- How Lundbeck's research on cerebrospinal fluid biomarkers and diagnostic tools for MSA will impact future clinical trials and disease management.